Follow the frequency (once-weekly) and recommended dose escalation schedule carefully to reduce stomach-related side effects
Later, multiple studies have further highlighted this concept by demonstrating that several agents attenuate CP-induced renal injury through dual suppression of both CP-induced apoptosis and necroptosis processes (Kim et al., 2019
A review of the clinical pharmacokinetics, pharmacodynamics, and immunogenicity of vedolizumab
The liver-targeted THR agonist resmetirom (MGL-3196) demonstrated significant reductions in hepatic lipid fraction and fibrosis, as well as plasma lipid and enzyme levels in patients with MASH, without affecting blood glucose or insulin levels (NCT02912260)
These medications, originally developed for diabetes management, have shown incredible effectiveness in helping individuals shed excess weight, manage cravings, and improve metabolic health